19.34
19.34 (0%)
As of Jan 24, 2025
Cadrenal Therapeutics, Inc. [CVKD]
Source:
Company Overview
Cadrenal Therapeutics, Inc. is focused on developing tecarfarin, a novel therapy with orphan drug indication, designed for the prevention of systemic thromboembolism (blood clots) of cardiac origin in patients with end-stage renal disease, or ESRD, and atrial fibrillation, or AFib.
Country | United States |
Headquarters | ponte vedra, florida |
Phone Number | 904-300-0701 |
Industry | |
CEO | Quang Pham |
Website | www.cadrenal.com |